NCT02997332 2026-03-23
MEDINDUCTION
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Terminated
Clinical Trials
50 trialsNCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT06083454 2026-03-13
Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)
University of Iowa
Phase 1 Terminated
NCT03753919 2026-03-11
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Terminated
NCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT05443971 2026-02-06
Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen
Mayo Clinic
Phase 1 Terminated
NCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT04765709 2025-12-16
BRIDGE
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT03237377 2025-10-14
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02938793 2025-09-23
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
Prisma Health-Upstate
Phase 2 Terminated
NCT04336943 2025-08-11
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
University of Washington
Phase 2 Terminated
NCT04019288 2025-06-11
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03277482 2025-05-31
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT04441138 2025-05-28
ESR1814205
Rush University Medical Center
Phase 2 Terminated
NCT04108481 2025-03-28
iRE-C
University of Iowa
Phase 1 Terminated
NCT05911308 2025-03-21
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT02827838 2025-03-17
Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
Wake Forest University Health Sciences
Phase EARLY_PHASE1 Terminated
NCT04322643 2025-02-25
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT06191250 2025-02-03
--SuPERIOR Trial--
University Health Network, Toronto
Phase 2 Terminated
NCT04364048 2024-12-20
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02891161 2024-11-27
DUART
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT04951115 2024-11-26
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT04287894 2024-11-06
Induction
The Netherlands Cancer Institute
Phase 1 Terminated
NCT04989218 2024-11-05
ICC
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT04348292 2024-08-22
Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
Emory University
Phase 1 Terminated
NCT03439085 2024-07-09
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03199040 2024-05-28
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Washington University School of Medicine
Phase 1 Terminated
NCT03810105 2024-04-09
A Study of Olaparib and Durvalumab in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT04610684 2024-03-13
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03818776 2024-02-15
Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT03376659 2024-02-05
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Georgetown University
Phase 1/2 Terminated
NCT03618134 2023-11-18
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
Jonsson Comprehensive Cancer Center
Phase 1/2 Terminated
NCT03490760 2023-10-12
Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas
Baptist Health South Florida
Phase 2 Terminated
NCT03912818 2023-09-11
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Phase 2 Terminated
NCT03963414 2023-08-28
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
University of Nebraska
Phase 1 Terminated
NCT04372927 2023-06-13
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
University of Washington
Phase 2 Terminated
NCT03522584 2023-06-12
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Washington
Phase 1/2 Terminated
NCT03275597 2023-05-15
Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition
University of Wisconsin, Madison
Phase 1 Terminated
NCT04696848 2023-04-21
The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
Asan Medical Center
Phase 1/2 Terminated
NCT03030131 2023-03-14
IONESCO
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Terminated
NCT02716805 2022-10-12
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT02706405 2022-08-24
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT02901548 2022-07-29
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03874325 2022-05-31
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT04579133 2021-06-16
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Latin American Cooperative Oncology Group
Phase 2 Terminated
NCT03081923 2021-05-14
APACHE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT03234153 2020-06-17
NITIMIB
Insel Gruppe AG, University Hospital Bern
Phase 2 Terminated
NCT02452463 2020-04-06
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
Roswell Park Cancer Institute
Phase 2 Terminated
NCT02669914 2018-11-06
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Washington University School of Medicine
Phase 2 Terminated